



# LAWS REGARDING CONTROLLED SUBSTANCES AND THE CONTROLLED SUBSTANCE ACT

Dr. Scott Penzak

**Recorded Webinar** 



## PROGRAM OVERVIEW

This CE presentation reviews federal, as well as Alabama-specific pharmacy laws, rules, and regulations that pertain to controlled substances. These laws, rules, and regulations apply to pharmacists practicing throughout the Alabama health-system. Knowledge of this information is required in order for pharmacists to successfully pass the Alabama MPJE. The registration fee for this program is \$25.

Following registration, participants will have access to course instructions, presentations, recorded webinar, program evaluation, CE certificates and credits, etc. **This program is approved for 4.5 ACPE Contact Hours, .450 CEUs.** Once credit is awarded, transcripts will be available online within 24 hours on the learner's CPE Monitor profile at <a href="http://nabp.pharmacy/">http://nabp.pharmacy/</a>.

The Office of Alumni and Professional Affairs strongly encourages each participant to check their profile online within 60 days of attendance to ensure credit has been awarded properly. ACPE will not accept CE submissions after 60 days from the live seminar date.

This program is not sponsored by an external organization.

### TARGET AUDIENCE

This knowledge-based program is intended for Pharmacists (ACPE).

## LEARNING OBJECTIVES

- · Explain the Controlled Substances Act
- Recognize the Schedules of Controlled Substances.
- Describe the required elements of controlled substance prescriptions
- Explain laws related to electronic prescribing (E-Prescribing) of controlled drugs
- Define laws pertaining to mid-level practitioners
- Identify regulations surrounding emergency filling of controlled substances.
- Define laws pertaining to Schedule III, IV, and V drugs including refills, partial filling, and how they may be ordered from a pharmacy (i.e., electronic, fax, phone, etc.).
- Outline opioid addiction treatment program laws, and all laws pertaining to the prescribing of methadone and buprenorphine +/- naloxone.
- Explain the role of the DEA in enforcing the Controlled Substances Act.
- Identify the legitimate handlers of controlled substances and their licensing requirements.
- Recognize the differences between Schedule I and Schedule II-V drugs in terms of medical use and abuse potential.
- · List the requirements for pharmacy registration with the DEA.
- Identify the procedures for renewing pharmacy registration.
- Explain the process for transferring business operations involving controlled substances.
- Recognize the requirements for ordering controlled substances using DEA Form 222 and the Controlled Substance Ordering System (CSOS).

## **ACTIVITY COMPLETION REQUIREMENTS**

To complete the steps for CE credit, each attendee will be required to access and review program materials located within the online course, view the recorded Zoom webinar, complete the quiz and program evaluation within the online course, and claim credit within the course. Please contact hcopce@auburn.edu if you have any questions or needs related to this online CE program.

#### **FACULTY DISCLOSURES**

Programming in with AUHCOP is in any way involved, whether as sole provider or joint-providership, shall exhibit fair content balance, providing the audience with information of multiple perspectives from which to form a professional opinion. In addition, the fair balance will assure than information provided does not discuss since commercial product. Brand names of all products included in the content may be mentioned for identification purposes only. Presenters in any continuing education offering will acknowledge and disclose any affiliation with the provider and such information will be made available to the audience.

Faculty disclosures will also be included on an introductory slide during the presentation.

Disclosures: There is no commercial support being received for this program. Dr. Penzak and others in control of content have no actual or potential conflict of interest in relation to this program.

## **ACCREDITATION INFORMATION**

The Auburn University Harrison College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education; credits are recognized nationwide. The Universal Activity Number for this knowledge-based program is **0001-0000-25-033-H03-P** and is intended for pharmacists. The initial release date for this home-study program is September 18, 2025, and the intended expiration date is September 18, 2028.

## PROGRAM FACULTY

**Scott Penzak**, Pharm.D. is Department Head and Professor in the Department of Pharmacy Practice, joining the Harrison School of Pharmacy on Dec. 1, 2018. Prior to joining the Harrison School of Pharmacy, Penzak totaled more than 12 years of experience as a researcher with the National Institutes of Health and nine years of academic experience at the University of North Texas and Mercer University.

Penzak is a 1990 graduate of Ferris State University with a bachelor of science degree in pharmacy. He went on to complete his Pharm.D. at Wayne State University in 1996. Upon graduation, he was a research fellow for two years at the University of Arkansas for Medical Sciences, studying infectious diseases pharmacology.

Penzak joined the HSOP faculty following a position at the University of North Texas Health Sciences Center in the College of Pharmacy from 2014-18. While there, he has served as professor and vice chair of the Department of Pharmacotherapy while also serving as interim associate dean for academic affairs from 2016-17.

Prior to his arrival at North Texas, Penzak spent 12 years as the director of the Clinical Pharmacokinetics Research Laboratory (CPRL) at the National Institutes of Health (NIH) in Bethesda, Maryland. He also spent three years (1998-2001) as an assistant professor of pharmacy practice at Mercer University.

Penzak's research is focused mainly on pharmacokinetics, pharmacogenetics, drug-drug, and drug-herb interactions with antiretroviral medications. From a clinical pharmacy service perspective, he routinely assists clinicians with therapeutic drug monitoring and drug interaction management in HIV-infected patients.

While with the NIH, Penzak was the director of the Clinical Pharmacokinetic Research Laboratory (CPRL), a unit that assists clinical investigators in the design, analysis, and interpretation of pharmacokinetic studies. The CPRL supports NIH scientists in several major areas of pharmacokinetic research, including drug interaction studies and characterization of drugs with nonlinear disposition. While director of the CPRL, he received three Directors Awards at NIH for scientific achievement (2005, 2013) and patient care (2012). In 2008 he was a recipient of the NIH Mentoring Award.

With research funding from organizations such as the NIH, American Association of Colleges of Pharmacy, and others, Penzak has generated more than 150 publications. He also serves on the editorial boards for publications such as the Journal of Clinical Pharmacology, Pharmacotherapy, European Journal of Drug Metabolism and Pharmacokinetics, and the International Journal of Pharmacokinetics. In 2017, Penzak was recognized as a Fellow in the American College of Clinical Pharmacology.

# POST-GRADUATE EDUCATION ADVISORY COMMITTEE

Spencer Durham, Pharm.D., BCPS, BCIDP

Associate Clinical Professor, Director of Alumni & Professional Affairs

Jack DeRuiter, Ph.D.

Alumni Professor, Drug Discovery and Development

Natalie Hohmann, Pharm.D., Ph.D.

Alumni Professor, Drug Discovery and Development

Erika Kleppinger, Pharm.D., BCPS

Associate Clinical Professor, Pharmacy Practice

Kristen Korankyi, Pharm.D.

Assistant Clinical Professor, Pharmacy Practice

Sylvia Rogers, Ph.D.

Senior Instructional Designer, Faculty Affairs and Strategic Initiatives

Abby Bell, BSN, RNC-OB

Clinical Placement and Nurse Apprenticeship Coordinator, AU College of Nursing

Brianna Foster

Program Administrator, Alumni and Professional Affairs

Tanja Redd, MBA, Ph.D.

Program Coordinator, Alumni and Professional Affairs

Members of the Post-Graduate Education Advisory Committee have completed a conflict-of-interest disclosure form and have no actual or potential conflicts of interest in relation to this program.